scholarly journals Clinical Outcomes of 67 Patients Treated with Chemoradiotherapy for Primary Thyroid Non-Hodgkin’s Lymphoma in Osaka Medical College

2016 ◽  
Vol 07 (05) ◽  
pp. 329-334
Author(s):  
Tsuyoshi Komori ◽  
Isamu Narabayashi ◽  
Yoshifumi Narumi ◽  
Taisuke Inomata
Keyword(s):  
Clinical Outcomes ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Osaka Medical College ◽  
Medical College ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma

2010 ◽  
Vol 28 (2) ◽  
pp. 279-284 ◽  
Author(s):  
Wen-Kai Weng ◽  
Robert S. Negrin ◽  
Philip Lavori ◽  
Sandra J. Horning
Keyword(s):  
B Cell ◽  
Clinical Outcomes ◽  
Immunoglobulin G ◽  
Hodgkin’S Lymphoma ◽  
Autologous Transplantation ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Post Transplantation ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Purpose Rituximab has been given after autologous hematopoietic cell transplantation for recurrent or refractory B-cell lymphoma with the goal of eradicating minimal residual disease. Our previous report showed that administration of two courses of rituximab after transplantation is feasible, with encouraging clinical outcomes after a short follow-up. However, neutropenia after the first or second post-transplantation rituximab treatment occurred in 52% of patients. We previously reported that polymorphisms of two immunoglobulin G Fc receptors predict rituximab response, presumably because of their role in antibody-dependent cellular cytotoxicity. In the current report, we determine whether FcγR polymorphisms are correlated with clinical outcomes in 33 patients with B-cell non-Hodgkin's lymphoma who received post-transplantation rituximab. Patients and Methods Genomic DNA was used for FcγRIIIa V/F or the FcγRIIa H/R genotyping. The FcγR polymorphisms were then correlated with the incidence of rituximab-induced neutropenia, event-free survival (EFS), and overall survival (OS). Results The FcγRIIIa 158 V allele dose was correlated with a higher incidence of rituximab-induced neutropenia. The odds of neutropenia after the first or second post-transplantation rituximab increased three-fold with each V allele (robust z = 2.08, P = .038). The FcγRIIa polymorphism had no impact on rituximab-induced neutropenia. We did not observe a correlation of either FcγRIIIa or FcγRIIa polymorphism with EFS or OS. Conclusion The high affinity FcγRIIIa 158 V allele is associated with rituximab-induced neutropenia after autologous transplantation. This is a potential tool to identify a high-risk population for developing neutropenia after antibody therapy.

Timing between Rituximab and 90Y-Ibritumomab Tiuxetan in Pts with Non-Hodgkin’s Lymphoma Does Not Affect Clinical Outcomes.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4735-4735
Author(s):  
Isaiah E. Friedman ◽  
Charalambos Andreadis ◽  
Yumi Taylor Diangi ◽  
Sunita D. Nasta ◽  
Selina M. Luger ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Antigen Specificity ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Group A ◽  
Aggressive Histology ◽  
Group B

Abstract BACKGROUND: Rituximab, a chimeric, monoclonal antibody that specifically targets CD20, is widely used in the treatment of non-Hodgkin’s lymphoma (NHL). 90Y ibritumomab tiuxetan (90Y-Iab) is the radiolabeled parent molecule of rituximab with the same antigen specificity and is currently approved for treatment of pts with relapsed or refractory low-grade, follicular, or transformed NHL. Most NHL pts in current practice are heavily exposed to rituximab (as opposed to pts in the early trials of 90Y-Iab) raising the concern for binding-site saturation translating into inferior clinical outcomes in this group. Since rituximab is detectable in the serum 6 mos after completion of treatment (Gordon et al, JCO23:1096–1102,2005), we tested the hypothesis that pts who receive 90Y-Iab within 6 mos of a standard four-week course of rituximab have inferior outcomes to pts who receive 90Y-Iab at least 6 mos after their last dose of rituximab. METHODS: Thirty-eight pts with NHL treated with a single course of 90Y-Iab between 1999 and 2006 were included in this retrospective, single-institution study. The median age was 59 y (range 21 – 83 y) and the median number of prior therapies was 4 (range 1 – 13). Overall, 21 pts had indolent NHL (17 follicular grade 1/2, 2 small lymphocytic, and 2 marginal zone), while 17 pts had aggressive NHL (11 diffuse large cell, 3 mantle cell, 2 follicular grade 3, and 1 PTLD). Among pts, 72% had stage III/IV disease, 42% had bulky lesions (>5 cm), and 58% had an elevated serum LDH. Median follow up was 17 mos (range 2 – 46 mos). RESULTS: In this cohort, progression-free survival (PFS) was significantly shorter for pts with aggressive lymphoma, compared to pts with indolent disease (HR=2.0, 95%CI: 1.02 – 4.0, p=.044). Overall survival (OS) was also significantly decreased for pts with aggressive histology (HR=4.6, 95%CI: 1.7 – 12.9, p=.004). In our analysis, 16 pts ( 42%) received 90Y-Iab within 6 mos of their last dose of rituximab (“group A”) and 22 pts (58%) received 90Y-lab at least 6 mos after their last dose of rituximab (“group B”). Overall response rate (CR + PR) was 38% in group A (95%CI: 15 – 65%) and 50% in group B (95% CI: 28 – 72%) (p=.52). PFS was not significantly different between the study groups: 3.8 mos in group A versus 3.0 mos in group B, even when stratified by histology (HR=0.98, 95%CI: 0.48 – 2.0, p=.96). Furthermore, the median OS was 21 mos in group A and 44 mos in group B, but was not significantly different for the two groups when stratified by histology (HR=0.55, 95%CI: 0.21 – 1.4, p=.21) since there was a disproportionate number of pts with aggressive histology in group A. CONCLUSIONS: Timing of 90Y-Iab in relation to rituximab had no effect on response rates, PFS, and OS in this retrospective analysis. To our knowledge, this is the only reported study to address this question and needs to be evaluated in additional cohorts. Given its limitations, our study suggests that treatment decisions regarding whether to administer 90Y-Iab to NHL pts should be made independent of whether rituximab was given in the previous six months.

Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

1993 ◽  
Vol 70 (04) ◽  
pp. 568-572 ◽  
Author(s):  
Roberto Stasi ◽  
Elisa Stipa ◽  
Mario Masi ◽  
Felicia Oliva ◽  
Alessandro Sciarra ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Clinical Significance ◽  
Antiphospholipid Antibodies ◽  
Myeloid Leukemia ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Tnf Alpha ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Acute Myeloid

SummaryThis study was designed to explore the prevalence and clinical significance of elevated antiphospholipid antibodies (APA) titres in patients affected by acute myeloid leukemia (AML) and highgrade non-Hodgkin’s lymphoma (NHL). We also analyzed possible correlations with circulating levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and the soluble form of the receptor for interleukin-2 (sIL-2r). Nineteen patients with de novo AML and 14 patients with newly-diagnosed NHL were investigated. Tests for APA included the measurement of anticardiolipin antibodies (ACA) with a solid-phase immunoassay, and the detection of the lupus-like anticoagulant (LA) activity. Five patients with AML (26.3%) and 5 patients with NHL (35.7%) presented elevated APA at diagnosis, as compared to 3 of 174 persons of the control group (p <0.0001). APA titres became normal in all patients responding to treatment, whereas nonresponders retained elevated levels. In addition, 6 patients (4 with AML and 2 with NHL), who had normal APA at diagnosis and were either refractory to treatment or in relapse, subsequently developed LA and/or ACA positivity. At presentation, the mean levels of IgG- and IgM-ACA in patients were not significantly different from Controls, and concordance between ACA and LA results reached just 30%. With regard to the clinical course, we were not able to detect any statistically significant difference between patients with normal and elevated APA. Pretreatment concentrations of IL-6 and TNF-alpha in AML, and sIL-2r in NHL were found significantly elevated compared to Controls (p = 0.003, p = 0.009 and p = 0.024 respectively). In addition, the levels of these cytokines correlated with IgG-ACA at the different times of laboratory investigations. These results demonstrate that APA may have a role as markers of disease activity and progression in some haematological malignancies.

Sign in / Sign up

Export Citation Format

Share Document